Maria Picchio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6000088/publications.pdf

Version: 2024-02-01

206 papers	8,463 citations	44069 48 h-index	48315 88 g-index
212 all docs	212 docs citations	212 times ranked	6493 citing authors

#	Article	IF	Citations
1	Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.7	18
2	State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review. Critical Reviews in Oncology/Hematology, 2022, 169, 103544.	4.4	16
3	68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data. Cancers, 2022, 14, 334.	3.7	13
4	Hybrid PET/MRI in Staging Endometrial Cancer. Clinical Nuclear Medicine, 2022, 47, e221-e229.	1.3	17
5	68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2352-2363.	6.4	20
6	PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. Cancers, 2022, 14, 1770.	3.7	21
7	18F-FDG PET/CT May Predict Tumor Type and Risk Score in Gestational Trophoblastic Disease. Clinical Nuclear Medicine, 2022, Publish Ahead of Print, .	1.3	5
8	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 554-560.	6.4	10
9	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. Diagnostics, 2021, 11, 192.	2.6	20
10	Reopening the country: Recommendations for nuclear medicine departments. World Journal of Nuclear Medicine, 2021, 20, 1-6.	0.5	6
11	18F-FAZA PET/CT in pretreatment assessment of hypoxic status in high-grade glioma: correlation with hypoxia immunohistochemical biomarkers. Nuclear Medicine Communications, 2021, 42, 763-771.	1.1	6
12	Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4002-4015.	6.4	31
13	AB0361â€…EFFECTIVENESS AND SAFETY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS: A REAL-LIFE EXPERIENCE FROM A MONOCENTRIC COHORT. Annals of the Rheumatic Diseases, 2021, 80, 1206.1-1206.	0.9	1
14	The Role of Positron Emission Tomography/Computed Tomography (PET/CT) for Staging and Disease Response Assessment in Localized and Locally Advanced Pancreatic Cancer. Cancers, 2021, 13, 4155.	3.7	8
15	Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients. Diagnostics, 2021, 11, 2068.	2.6	17
16	Synergic role of preoperative 18F-fluorodeoxyglucose PET and MRI parameters in predicting histopathological features of endometrial cancer. Nuclear Medicine Communications, 2020, 41, 1073-1080.	1.1	8
17	Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer. Radiotherapy and Oncology, 2020, 153, 258-264.	0.6	19
18	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nuclear Medicine Communications, 2020, 41, 896-905.	1.1	28

#	Article	IF	Citations
19	Pancreatic metastases from primary ileal NET only detected by 68Ga-DOTATOC PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2713-2714.	6.4	0
20	Hypoxia and Amino Acid Imaging of High-Grade Glioma. Clinical Nuclear Medicine, 2020, 45, e290-e293.	1.3	1
21	Hypoxia PET imaging beyond 18F-FMISO in patients with high-grade glioma: 18F-FAZA and other hypoxia radiotracers. Clinical and Translational Imaging, 2020, 8, 11-20.	2.1	14
22	18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma. International Journal of Biological Markers, 2020, 35, 42-46.	1.8	12
23	Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1779-1786.	6.4	24
24	Defining the Right State for a Will Rogers Phenomenon in Oligometastatic Prostate Cancer. JAMA Oncology, 2020, 6, 936.	7.1	0
25	FRI0214â€...PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE. Annals of the Rheumatic Diseases, 2020, 79, 690.2-691.	0.9	0
26	Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20â€‰ng/mL. Nuclear Medicine Communications, 2020, 41, 1178-1182.	1.1	0
27	Oligorecurrent prostate cancer limited to lymph nodes: getting our ducks in a row. World Journal of Urology, 2019, 37, 2607-2613.	2.2	18
28	EP-1907 Which FDG-PET features are robust enough for Radiomic studies in pancreatic cancer patients?. Radiotherapy and Oncology, 2019, 133, S1036-S1037.	0.6	0
29	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. Clinical and Translational Imaging, 2019, 7, 363-371.	2.1	4
30	Hybrid cardiac PET/MR: the value of multiparametric assessment in cardiac sarcoidosis. Clinical and Translational Imaging, 2019, 7, 317-326.	2.1	4
31	18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosisâ€”A Multicenter Retrospective Study. Cancers, 2019, 11, 700.	3.7	23
32	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clinical and Translational Imaging, 2019, 7, 181-188.	2.1	18
33	PET/MRI in Neuroendocrine Tumours: Blessings and Curses. Current Radiopharmaceuticals, 2019, 12, 96-97.	0.8	7
34	The â€œRadicalâ€•Palliation That Increases Survival in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, e282-e283.	1.1	1
35	Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels. Nuclear Medicine Communications, 2019, 40, 258-263.	1.1	3
36	Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patients. Nuclear Medicine Communications, 2019, 40, 1072-1080.	1.1	1

#	Article	IF	Citations
37	Moderately Hypofractionated Helical IMRT, FDGâ€“PET/CT-guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs. Clinical Lung Cancer, 2019, 20, e29-e38.	2.6	8
38	Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer. Clinical and Translational Imaging, 2019, 7, 39-44.	2.1	5
39	FunciÃ³n pronÃ³stica de los parÃ¡metros derivados de FDG PET en la estadificaciÃ³n preoperatoria del cÃ¡ncer de endometrio. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2019, 38, 3-9.	0.0	5
40	11C-choline PET/CT predicts survival in prostate cancer patients with PSAâ€‰<â€‰1 NG/ml. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 921-929.	6.4	14
41	The relationship between local recurrences and distant metastases in prostate cancer: can 11C-choline PET/CT contribute to understand the link?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 962-969.	6.4	1
42	Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. Abdominal Radiology, 2018, 43, 2391-2399.	2.1	23
43	68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 686-693.	3.1	195
44	Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 85-94.	6.4	20
45	Added diagnostic value of respiratory-gated 4D 18Fâ€“FDG PET/CT in the detection of liver lesions: a multicenter study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 102-109.	6.4	22
46	Quantifying the robustness of [18 F]FDG-PET/CT radiomic features with respect to tumor delineation in head and neck and pancreatic cancer patients. Physica Medica, 2018, 49, 105-111.	0.7	50
47	EP-1221: Hypoxia imaging with 18F-FAZA PET/CT in Radiotherapy Planning for High Grade Gliomas. Radiotherapy and Oncology, 2018, 127, S678.	0.6	0
48	EP-1390: Salvage (postponed) hypofractionated tomotherapy for progressive MPM in patients with intact lungs. Radiotherapy and Oncology, 2018, 127, S759.	0.6	0
49	18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry. Current Radiopharmaceuticals, 2018, 11, 50-57.	0.8	7
50	Diffusion-Weighted Magnetic Resonance Imaging Detects Vessel Wall Inflammation in Patients With GiantÂCellÂArteritis. JACC: Cardiovascular Imaging, 2018, 11, 1879-1882.	5.3	22
51	FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2071-2078.	6.4	8
52	Toxicity and efficacy of salvage carbon 11â€choline positron emission tomography/computed tomographyâ€guided radiation therapy in patients with lymph node recurrence of prostate cancer. BJU International, 2017, 119, 406-413.	2.5	43
53	Re: Daniel E. Spratt, Herbert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71;37â€“43. European Urology, 2017, 71, e179-e180.	1.9	2
54	First Evaluation of PET-Based Human Biodistribution and Dosimetry of ¹⁸F-FAZA, a Tracer for Imaging Tumor Hypoxia. Journal of Nuclear Medicine, 2017, 58, 1224-1229.	5.0	35

#	Article	IF	Citations
55	FDG Uptake by Prosthetic Arterial Grafts in Large Vessel Vasculitis Is NotÂSpecific for Active Disease. JACC: Cardiovascular Imaging, 2017, 10, 1042-1052.	5.3	31
56	18F-FDG PET reveals unique features of large vessel inflammation in patients with Takayasuâ€™s arteritis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1109-1118.	6.4	53
57	The Authors Reply:. JACC: Cardiovascular Imaging, 2017, 10, 607-608.	5.3	0
58	Concomitant Lung Cancer and Gastrointestinal Stromal Tumor. Clinical Nuclear Medicine, 2017, 42, e349-e351.	1.3	7
59	Clinical PET imaging of tumour hypoxia in lung cancer. Clinical and Translational Imaging, 2017, 5, 427-445.	2.1	0
60	18F-FAZA PET/CT Hypoxia Imaging of High-Grade Glioma Before and After Radiotherapy. Clinical Nuclear Medicine, 2017, 42, e525-e526.	1.3	13
61	When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging. Urology, 2017, 110, 114-120.	1.0	5
62	EP-1315: Prostate cancer lymph nodal disease: SBRT only or extensive prophylactic irradiation and boost?. Radiotherapy and Oncology, 2017, 123, S704-S705.	0.6	0
63	EP-1319: â€œAdjuvantâ€ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis. Radiotherapy and Oncology, 2017, 123, S707-S708.	0.6	0
64	Hypoxia 18F-FAZA PET/CT imaging in lung cancer and high-grade glioma: open issues in clinical application. Clinical and Translational Imaging, 2017, 5, 389-397.	2.1	9
65	PO-0886: Early changes of FDG-PET markers predict the outcome after chemo-radiotherapy for pancreatic cancer. Radiotherapy and Oncology, 2017, 123, S486-S487.	0.6	0
66	PD11-01 COMPARISON BETWEEN THE DIAGNOSTIC ACCURACIES OF 18F-FLUORODEOXYGLUCOSE (FDG) POSITRON EMISSION TOMOGRAPHY (PET)/COMPUTED TOMOGRAPHY (CT) AND MORPHOLOGICAL IMAGING IN RECURRENT UROTHELIAL CARCINOMAS: A RETROSPECTIVE, MULTI-CENTER STUDY. Journal of Urology, 2017, 197, .	0.4	0
67	EP-1678: Are PET radiomic features robust enough with respect to tumor delineation uncertainties?. Radiotherapy and Oncology, 2017, 123, S915.	0.6	0
68	Current status and future perspectives of PET/MRI hybrid imaging. Clinical and Translational Imaging, 2017, 5, 79-81.	2.1	3
69	Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 344-345.	6.4	0
70	PET imaging for lymph node dissection in prostate cancer. World Journal of Urology, 2017, 35, 507-515.	2.2	9
71	18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 589-597.	6.4	51
72	Detection of Bone Metastases and Evaluation of Therapy Response in Prostate Cancer Patients by Radiolabelled Choline PET/CT. , 2017, , 75-85.		1

#	Article	IF	Citations
73	FDG-PET/CT Predicts Outcome in Oropharingeal Carcinoma Patients Undergoing Intensity Modulated Radiation Therapy with Dose Escalation to FDG-avid Tumour Volumes. Current Radiopharmaceuticals, 2017, 10, 102-110.	0.8	3
74	11C-Choline PET/CT based Helical Tomotherapy as Treatment Approach for Bone Metastases in Recurrent Prostate Cancer Patients. Current Radiopharmaceuticals, 2017, 10, 195-202.	0.8	5
75	Role of PET/CT in Radiotherapy Treatment Planning. , 2017, , 577-608.		1
76	PET/MRI and prostate cancer. Clinical and Translational Imaging, 2016, 4, 473-485.	2.1	13
77	Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161â€“75. European Urology, 2016, 70, e114-e115.	1.9	2
78	Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC). European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1837-1848.	6.4	35
79	¹¹C- or ¹⁸F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 43S-48S.	5.0	42
80	Evaluation of Prostate Cancer with ¹¹C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. Journal of Nuclear Medicine, 2016, 57, 49S-54S.	5.0	25
81	PO-0689: Outcome predictors for moderate hypofractionated tomotherapy in Malignant Pleural Mesothelioma. Radiotherapy and Oncology, 2016, 119, S322.	0.6	0
82	PET/MRI in gynecological tumors. Clinical and Translational Imaging, 2016, 4, 211-220.	2.1	12
83	EP-1079: Clinical outcomes in locally advanced oropharyngeal cancer 18FDG PET-guided dose escalation IMRT-SIB. Radiotherapy and Oncology, 2016, 119, S518-S519.	0.6	0
84	EP-1852: Predictive role of FDG-PET/CT image-derived parameters in locally advanced oropharyngeal cancer. Radiotherapy and Oncology, 2016, 119, S871-S872.	0.6	0
85	EP-1347: Could â€œradicalâ€•RT be a reasonable choice in bone oligometastatic prostate cancer patients?. Radiotherapy and Oncology, 2016, 119, S629-S630.	0.6	0
86	SAT0350â€…Functional Characterisation of Takayasu Arteritis Vascular Lesions by MR and FDG-PET/CT Provides Non-Redundant Information over Clinical Assessment. Annals of the Rheumatic Diseases, 2016, 75, 793.3-794.	0.9	0
87	PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment. Physica Medica, 2016, 32, 452-458.	0.7	6
88	New Clinical Indications for 18 F/ 11 C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. European Urology, 2016, 70, 161-175.	1.9	184
89	Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 404-413.	6.4	47
90	Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 464-473.	6.4	79

#	Article	IF	Citations
91	PD38-12 [11C]CHOLINE PET/CT PREDICTS SURVIVAL IN HORMONE NAÃVE PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.4	2
92	18F-FDG PET/CT for Early Postradiotherapy Assessment in Solitary Bone Plasmacytomas. Clinical Nuclear Medicine, 2015, 40, e399-e404.	1.3	16
93	Radiation Treatment of Lymph Node Recurrence from Prostate Cancer: Is ¹¹C-Choline PET/CT Predictive of Survival Outcomes?. Journal of Nuclear Medicine, 2015, 56, 1836-1842.	5.0	35
94	Imaging biomarkers in prostate cancer: role of PET/CT and MRI. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 644-655.	6.4	57
95	[11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 877-884.	6.4	38
96	Initial prostate cancer diagnosis and disease stagingâ€"the role of choline-PETâ€"CT. Nature Reviews Urology, 2015, 12, 510-518.	3.8	34
97	Prostate cancer recurrence: can PSA guide imaging?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1781-1783.	6.4	6
98	Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. European Urology, 2015, 67, 299-309.	1.9	211
99	AB0572â€...Additional Role of FDG Pet/Ct in the Assessment of Disease Activity in Takayasu Arteritis. Annals of the Rheumatic Diseases, 2014, 73, 995.2-995.	0.9	0
100	PD15-07 ASSESSING THE OPTIMAL EXTENT OF SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH SINGLE PELVIC NODAL UPTAKE AT [11C]-CHOLINE PET/CT SCAN FROM RECURRING PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.4	0
101	Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: Results from a pathologically validated series. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 38.e9-38.e16.	1.6	61
102	Writing PET into existence. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 7-10.	6.4	2
103	Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 21-31.	6.4	60
104	11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1270-9.	6.4	72
105	¹¹C-Choline PET/CT Predicts Prostate Cancerâ€"Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy. Journal of Nuclear Medicine, 2014, 55, 233-241.	5.0	91
106	Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 505-513.	6.4	48
107	Prostate cancer imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1-4.	6.4	5
108	11C-Choline PET/CT and PSA kinetics. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 36-40.	6.4	42

#	Article	IF	Citations
109	PET/MRI. Clinical and Translational Imaging, 2013, 1, 3-4.	2.1	6
110	Sarcoidosis mimicking metastatic gynaecological malignancies: A diagnostic and therapeutic challenge?. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2013, 32, 314-317.	0.0	6
111	Spinal cord involvement secondary to non-Hodgkin's lymphoma identified by 18F-FDG PET/CT. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2013, 32, 125.	0.0	1
112	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography for Early Detection of Prostate Cancer Recurrence in Patients with Low Increasing Prostate Specific Antigen. Journal of Urology, 2013, 189, 105-110.	0.4	42
113	Comparison of ¹⁸F-Fluoroazomycin-Arabinofuranoside and ⁶⁴Cu-Diacetyl-Bis(N4-Methylthiosemicarbazone) in Preclinical Models of Cancer. Journal of Nuclear Medicine, 2013, 54, 1106-1112.	5.0	21
114	Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical Prostatectomy. Clinical Nuclear Medicine, 2013, 38, e26-e32.	1.3	72
115	Prostate-Specific Antigen Velocity Versus Prostate-Specific Antigen Doubling Time for Prediction of 11C Choline PET/CT in Prostate Cancer Patients With Biochemical Failure After Radical Prostatectomy. Clinical Nuclear Medicine, 2012, 37, 325-331.	1.3	45
116	Incidental Finding of Parathyroid Adenoma With 11C-Choline PET/CT. Clinical Nuclear Medicine, 2012, 37, 593-595.	1.3	54
117	178 A SINGLE SPOT AT [(11)C]CHOLINE-PET/CT SCAN IS NOT PREDICTIVE OF A SINGLE, ISOLATED NODAL METASTASIS AT FINAL PATHOLOGY. IMPLICATIONS FOR SALVAGE TREATMENTS. Journal of Urology, 2012, 187, .	0.4	0
118	182 EVALUATION OF LYMPH NODE RECURRENT PROSTATE CANCER WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL PROSTATECTOMY: VALIDATION BY HISTOLOGICAL ANALYSIS. Journal of Urology, 2012, 187, .	0.4	0
119	187 IS [11C]CHOLINE PET/CT RECOMMENDED FOR RESTAGING PROSTATE CANCER PATIENTS AFTER RADICAL PROSTATECTOMY WHEN PSA IS LOWER THAN 1 NG/ML?. Journal of Urology, 2012, 187, .	0.4	0
120	Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2012, 31, 207-209.	0.0	7
121	Clinical Indications of 11C-Choline PET/CT in Prostate Cancer Patients with Biochemical Relapse. Theranostics, 2012, 2, 313-317.	10.0	27
122	Motion Management in Positron Emission Tomography/Computed Tomography for Radiation Treatment Planning. Seminars in Nuclear Medicine, 2012, 42, 289-307.	4.6	32
123	Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1381-1390.	6.4	50
124	The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Annals of Nuclear Medicine, 2012, 26, 451-461.	2.2	94
125	Reply to the letter â€œCholine PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patientsâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 912-913.	6.4	3
126	[11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 13-26.	6.4	147

#	Article	IF	Citations
127	Role of PET/CT in the clinical management of locally advanced pancreatic cancer. Tumori, 2012, 98, 643-51.	1.1	6
128	Molecular imaging for prostate cancer diagnosing and for guiding tailored therapies. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2012, 56, 319-20.	0.7	0
129	Clinical and diagnostic assessment for therapeutic decisions in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2012, 56, 321-30.	0.7	8
130	Physical Performance of the new hybrid PET/CT Discovery-690. Medical Physics, 2011, 38, 5394-5411.	3.0	326
131	The role of PET/computed tomography scan in the management of prostate cancer. Current Opinion in Urology, 2011, 21, 230-236.	1.8	29
132	Imaging of a Thymoma Incidentally Detected by C-11 Choline PET/CT. Clinical Nuclear Medicine, 2011, 36, 134-135.	1.3	15
133	Preoperative staging of cervical cancer: Is 18-FDG-PET/CT really effective in patients with early stage disease?. Gynecologic Oncology, 2011, 123, 236-240.	1.4	74
134	The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. European Urology, 2011, 59, 51-60.	1.9	177
135	Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. European Urology, 2011, 60, 935-943.	1.9	209
136	Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. Eur Urol 2011;59:572â€“83. European Urology, 2011, 60, e37-e38.	1.9	10
137	The rising PET: the increasing use of choline PET/CT in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 53-54.	6.4	10
138	Performance of beta- and high-energy gamma probes for the detection of cancer tissue in experimental surgical resection beds. Annals of Nuclear Medicine, 2011, 25, 486-493.	2.2	12
139	Combined Use of TBNA and EBUS-TBNA in the Preoperative Staging of Lung Cancer Patients. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 311-316.	1.4	4
140	33 oral: Role of 11C-Choline PET/CT In Tomotherapy Treatment Planning of Lymph Nodal Relapse in Prostate Cancer Patients. Radiotherapy and Oncology, 2010, 94, S13.	0.6	0
141	Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 301-309.	6.4	258
142	PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1106-1116.	6.4	119
143	When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. European Urology, 2010, 57, 551-558.	1.9	137
144	[¹¹C]choline-PET-guided Helical Tomotherapy and Estramustine in a Patient with Pelvic-Recurrent Prostate Cancer: Local Control and Toxicity Profile after 24 Months. Tumori, 2010, 96, 613-617.	1.1	9

#	Article	IF	Citations
145	2017 FACTORS PREDICTING POSITIVE [11C]CHOLINE PET/CT IN PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2010, 183, .	0.4	0
146	[¹¹ C]Choline Positron Emission Tomography/Computerized Tomography to Restage Prostate Cancer Cases With Biochemical Failure After Radical Prostatectomy and No Disease Evidence on Conventional Imaging. Journal of Urology, 2010, 184, 938-943.	0.4	74
147	155 [11C]CHOLINE PET/CT FOR RESTAGING PROSTATE CANCER PATIENTS WITH BIOCHEMICAL FAILURE AFTER RADICAL PROSTATECTOMY AND NO EVIDENCE OF DISEASE ON CONVENTIONAL IMAGING. European Urology Supplements, 2010, 9, 80-81.	0.1	0
148	Detection and compensation of organ/lesion motion using 4D-PET/CT respiratory gated acquisition techniques. Radiotherapy and Oncology, 2010, 96, 311-316.	0.6	54
149	Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. Radiotherapy and Oncology, 2010, 96, 347-350.	0.6	49
150	High-grade endometrial cancer: value of [18F]FDG PET/CT in preoperative staging. Nuclear Medicine Communications, 2010, 31, 506-512.	1.1	73
151	[11C]Meta-Hydroxyephedrine PET/CT. Current Radiopharmaceuticals, 2010, 3, 275-283.	0.8	1
152	Carcinoma prostatico e ruolo della PET-TC. , 2010, , 163-169.		0
153	PET/CT for radiotherapy: image acquisition and data processing. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2010, 54, 455-75.	0.7	10
154	[11C]choline-PET-guided helical tomotherapy and estramustine in a patient with pelvic-recurrent prostate cancer: local control and toxicity profile after 24 months. Tumori, 2010, 96, 613-7.	1.1	6
155	Changes in Glucose Metabolism during and after Radiotherapy in Non-Small Cell Lung Cancer. Tumori, 2009, 95, 177-184.	1.1	12
156	Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: Detection of pelvic nodal metastases. Gynecologic Oncology, 2009, 115, 231-235.	1.4	114
157	Characterization of preclinical models of prostate cancer using PET-based molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1245-1255.	6.4	5
158	Positron emission tomography/computed tomography introduction in the clinical management of patients with suspected recurrence of ovarian cancer: a cost-effectiveness analysis. European Journal of Cancer Care, 2009, 18, 612-619.	1.5	27
159	Helical Tomotherapy for the Treatment of Isolated Lung Lesions: A Feasibility Study. International Journal of Radiation Oncology Biology Physics, 2009, 75, S472.	0.8	0
160	DETECTION OF LYMPH-NODE METASTASES WITH INTEGRATED [11C]CHOLINE PET/CT IN PATIENTS WITH PSA FAILURE AFTER RADICAL RETROPUBIC PROSTATECTOMY: VALIDATION BY OPEN PELVIC-RETROPERITONEAL LYMPHADENECTOMY. Journal of Urology, 2009, 181, 829-829.	0.4	1
161	A NOVEL NOMOGRAM PREDICTING A POSITIVE [11 C]CHOLINE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY (PET/TC) SCAN IN PATIENTS WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2009, 181, 781-781.	0.4	0
162	VALIDATION OF THE CRITERIA SUGGESTED BY CURRENT GUIDELINES TO INDICATE THE NEED FOR BASELINE STAGING BONE SCAN IN PATIENTS WITH NEWLY DIAGNOSED PROSTATE CANCER. Journal of Urology, 2009, 181, 782-782.	0.4	3

#	Article	IF	Citations
163	C-11 Choline Versus F-18 Fluorodeoxyglucose for Imaging Meningiomas. Clinical Nuclear Medicine, 2009, 34, 7-10.	1.3	53
164	Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers. Journal of Thoracic Oncology, 2009, 4, 1352-1356.	1.1	30
165	Incidental detection by [11C]choline PET/CT of meningiomas in prostate cancer patients. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 417-21.	0.7	30
166	PET-CT for treatment planning in prostate cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2009, 53, 245-68.	0.7	37
167	[11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1065-1073.	6.4	171
168	11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms. European Urology, 2008, 54, 392-401.	1.9	232
169	PET/CT and Breast Cancer. , 2008, , 217-226.		0
170	Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by ¹⁸F-FAZA and ¹²⁵I-Gluco-RGD Autoradiography. Journal of Nuclear Medicine, 2008, 49, 597-605.	5.0	38
171	Increased [11C]Choline Uptake in Bronchioloalveolar Cell Carcinoma with Negative [18F]FDG Uptake. A PET/CT and Pathology Study. Current Radiopharmaceuticals, 2008, 1, 62-64.	0.8	0
172	Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine. Journal of Nuclear Medicine, 2007, 48, 973-980.	5.0	92
173	Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: Correlation with transvaginal ultrasonography, computed tomography, and histology. Nuclear Medicine Communications, 2007, 28, 589-595.	1.1	168
174	Detection of Lymph-Node Metastases with Integrated [11C]Choline PET/CT in Patients with PSA Failure after Radical Retropubic Prostatectomy: Results Confirmed by Open Pelvic-Retroperitoneal Lymphadenectomy. European Urology, 2007, 52, 423-429.	1.9	232
175	Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 472-479.	6.4	86
176	Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 658-666.	6.4	101
177	Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1566-1575.	6.4	168
178	Positron detection for the intraoperative localisation of cancer deposits. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1534-1544.	6.4	60
179	Two-dimensional vs three-dimensional imaging in whole body oncologic PET/CT: a Discovery-STE phantom and patient study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007, 51, 214-23.	0.7	15
180	Bone metastases are infrequent in patients with newly diagnosed prostate cancer: Analysis of their clinical and pathologic features. Urology, 2006, 68, 362-366.	1.0	16

#	Article	IF	Citations
181	Lymph Node Metastasis in Patients with Clinical Early-Stage Cervical Cancer: Detection with Integrated FDG PET/CT. Radiology, 2006, 238, 272-279.	7.3	292
182	PET/CT and radiotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2006, 50, 4-14.	0.7	40
183	Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. Journal of Nuclear Medicine, 2006, 47, 938-44.	5.0	92
184	Thresholding Segmentation of FDG PET Lung Lesions for RT Planning Purposes. International Journal of Radiation Oncology Biology Physics, 2005, 63, S403-S404.	0.8	2
185	Positron Emission Tomography for Radiation Treatment Planning. Strahlentherapie Und Onkologie, 2005, 181, 483-499.	2.0	187
186	369 PET/CT guided helical tomotherapy in patients with locally advanced pancreatic cancer. Radiotherapy and Oncology, 2005, 76, S165-S166.	0.6	1
187	374 Role of PET/CT in monitoring patients during RT treatment for lung cancer. Radiotherapy and Oncology, 2005, 76, S167.	0.6	0
188	375 Segmentation of FDG PET Lung Lesions based on a thresholding approach for BTV definition. Radiotherapy and Oncology, 2005, 76, S167.	0.6	0
189	Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. Journal of Nuclear Medicine, 2005, 46, 106-13.	5.0	224
190	Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings. Radiology, 2004, 233, 433-440.	7.3	162
191	Diagnosis of local recurrence after radical prostatectomy. BJU International, 2004, 93, 680-688.	2.5	65
192	Is 11 C-choline the most appropriate tracer for prostate cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 753-755.	6.4	14
193	Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, 932-939.	6.4	101
194	PET/CT and breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S135-S142.	6.4	98
195	PET/CT in diagnostic oncology. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2004, 48, 66-75.	0.7	31
196	[18f]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients. Gynecologic Oncology, 2003, 91, 226-230.	1.4	25
197	Fluorodeoxyglucose positron emission tomography improves preoperative staging of resectable lung metastasis. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 1906-1910.	0.8	77
198	Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet, The, 2003, 362, 593-597.	13.7	422

#	Article	IF	Citations
199	Value of [¹¹ C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [¹⁸ F]fluorodeoxyglucose-Positron Emission Tomography. Journal of Urology, 2003, 169, 1337-1340.	0.4	316
200	Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2003, 47, 77-84.	0.5	10
201	Evaluation of the clinical performances of a large NaI(Tl) crystal 3D PET scanner. The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2003, 47, 90-100.	0.5	0
202	Positive [¹¹C]Choline and Negative [¹⁸F]FDG with Positron Emission Tomography in Recurrence of Prostate Cancer. American Journal of Roentgenology, 2002, 179, 482-484.	2.2	29
203	Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases. British Journal of Cancer, 2002, 86, 1391-1395.	6.4	21
204	High prevalence of (99m)tc-tetrofosmin reverse perfusion pattern in patients with myocardial infarction and angiographically smooth coronary arteries. International Journal of Cardiovascular Imaging, 2002, 18, 31-40.	0.6	3
205	18F-FDG PET/MRI in endometrial cancer: systematic review and meta-analysis. Clinical and Translational Imaging, 0, , 1.	2.1	4
206	Decoding the Heterogeneity of Malignant Gliomas by PET and MRI for Spatial Habitat Analysis of Hypoxia, Perfusion, and Diffusion Imaging: A Preliminary Study. Frontiers in Neuroscience, 0, 16, .	2.8	5